[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355883-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355883-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impdh1-is-a-potential-immune-evasion-related-oncoprotein-in-endometrial-cancer","IMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer","","Endometrial cancer is one of the most common gynecologic malignancies, with increasing evidence suggesting the involvement of immune-related processes rather than direct immune evasion mechanisms in its progression. However, effective immune-related biomarkers for prognostic evaluation and therapeutic targeting remain limited. This study used integrated proteomic and bioinformatic analyses on clinical specimens to identify immune-associated molecules. IMPDH1 was upregulated and linked to unfavorable prognosis, reduced CD8+ T cell infiltration, and an immunosuppressive tumor microenvironment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impdh1-is-a-potential-immune-evasion-related-oncoprotein-in-endometrial-cancer/355883/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impdh1-is-a-potential-immune-evasion-related-oncoprotein-in-endometrial-cancer/355883.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal for endometrial cancer?","Question",{"text":63,"@type":64},"Identify novel immune-associated molecules using integrated proteomic and bioinformatic approaches based on clinical endometrial cancer specimens.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is IMPDH1 related to endometrial cancer outcomes?",{"text":68,"@type":64},"IMPDH1 is significantly upregulated in endometrial cancer and is associated with unfavorable prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What does high IMPDH1 expression suggest about the tumor immune microenvironment?",{"text":72,"@type":64},"High IMPDH1 expression correlates with reduced CD8+ T cell infiltration and features of an immunosuppressive tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355883,1790321330,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Chen et al. BMC Genomic Data (2026) 27:46 [https://doi.org/10.1186/s12863-026-01427-5](https://doi.org/10.1186/s12863-026-01427-5)  \nBMC Genomic Data  \nRESEARCH Open Access  \nIMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer  \nYongning Chen1†, Fei Ma2†, Weichang Chen3, Ruibin Jiang3, Fei Wu1, Shipeng Gong1* andYadi Zhang1*  \nAbstract  \nEndometrial cancer is one of the most common gynecologic malignancies, with increasing evidence suggesting the involvement of immune-related processes rather than direct immune evasion mechanisms in its progression. However, effective immune-related biomarkers for prognostic evaluation and therapeutic targeting remain limited. This study aimed to identify novel immune-associated molecules based on clinical endometrial cancer specimens using integrated proteomic and bioinformatic approaches. Proteomic analysis was performed on tumor and adjacent normal tissues from endometrial cancer patients. Differentially expressed proteins were screened and further analyzed through transcriptomic validation, survival analysis, immune infiltration assessment, and pathway enrichment to explore their clinical relevance and potential functional roles in the tumor immune microenvironment. IMPDH1 was identified as a significantly upregulated protein in endometrial cancer and was associated with unfavorable prognosis. High expression of IMPDH1 was correlated with reduced CD8⁺ T cell infiltration and features of an immunosuppressive tumor microenvironment. Functional enrichment suggested its involvement in purine metabolism and a potential role in immune-related processes. This study identifies IMPDH1 as a novel immune-related biomarker in endometrial cancer, with potential value for prognosis and immunotherapy.  \nKeywords Endometrial cancer, IMPDH1, Immune evasion, CD8⁺ T cells, Proteomics  \n†Yongning Chen and Fei Ma contributed equally to this work.  \n*Correspondence: Shipeng Gong [gsp2103@163.com](gsp2103@163.com)[ ](gsp2103@163.com)Yadi Zhang [flyou@smu.edu.cn](flyou@smu.edu.cn)  \n1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China 2Department of Ultrasonography, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China  \n3The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China  \nIntroduction  \nEndometrial cancer (EC) is the most common gynecologic malignancy in developed countries, and its incidence continues to rise globally, particularly in younger and obese populations [1]. While most early-stage EC cases are effectively managed by surgery and adjuvant therapies, with a five-year survival rate of approximately 95% for localized disease, the prognosis of advanced, recurrent, or high-grade tumors remains poor due to limited treatment efficacy and high rates of relapse, with five-year survival dropping to around 16–18% for distantstage disease [2]. Despite recent advances in molecular classification, the therapeutic landscape for EC has not significantly changed for decades – standard treatments have remained largely unchanged – highlighting the  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the mater","cbCaikKL1NV9Fo7f","https://ap.wps.com/l/cbCaikKL1NV9Fo7f","pdf",2596095,12,"English","# Introduction\n## Immune processes and immunotherapy challenges\n## Rationale and role of IMPDH1","[{\"question\":\"What is the study’s main goal for endometrial cancer?\",\"answer\":\"Identify novel immune-associated molecules using integrated proteomic and bioinformatic approaches based on clinical endometrial cancer specimens.\"},{\"question\":\"How is IMPDH1 related to endometrial cancer outcomes?\",\"answer\":\"IMPDH1 is significantly upregulated in endometrial cancer and is associated with unfavorable prognosis.\"},{\"question\":\"What does high IMPDH1 expression suggest about the tumor immune microenvironment?\",\"answer\":\"High IMPDH1 expression correlates with reduced CD8+ T cell infiltration and features of an immunosuppressive tumor microenvironment.\"}]","IMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer | PDF",1790121512,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46f338ee1ef04a754909bb2f2abaeb0e.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/859b8d2d516b97fabad29e46f4d68632.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b088ed78340b56c26376a19cd0345b5.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0765856ebce48b21d6761cf009cb9a22.webp",980,1306]